NORCROSS, Ga., April 12 /PRNewswire-FirstCall/ -- Immucor, Inc. , the global leader in providing automated instrument-reagent systems to the blood transfusion industry, today announced that the U.S. Food and Drug Administration has cleared the Company's Capture-S and CMV Assays for use on the Galileo instrument. Galileo is Immucor's fully automated walk-away instrument for the hospital blood bank transfusion laboratory, donor centers and reference laboratories.
Commenting on this clearance, Dr. Gioacchino De Chirico, President stated, "We expect this test menu expansion will result in increased penetration of the donor center market with the Galileo."
Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Immucor markets a complete family of automated instrumentation for all of our market segments.
For more information on Immucor, please visit our website at www.immucor.com.
Statements contained in this press release that are not statements of historical fact are "forward-looking statements" as that term is defined under federal securities laws, including, without limitation, all statements concerning Immucor's expectations, beliefs, intentions or strategies for the future. Forward-looking statements may be identified by words such as "plans," "expects," "believes," "anticipates," "estimates," "projects," "will," "should" and other words of similar meaning. Investors are cautioned not to place undue reliance on any forward-looking statements. Achievement of these results may be adversely impacted by, among other things, the inability of customers to effectively integrate our Galileo instruments into their blood testing operations. Further risks are detailed in the Company's filings with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on any forward-looking statements. Immucor assumes no obligation to update any forward-looking statements.
Immucor, Inc.CONTACT: Edward Gallup of Immucor, Inc., +1-770-441-2051
Web site: http://www.immucor.com//